Moderna lays out plan for mRNA-1273 vaccine

By The Science Advisory Board staff writers

May 19, 2020 -- Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Based on the results, the company plans to begin a phase III study in July.

In the phase I study, patients were dosed at 25 µg or 100 µg; all participants seroconverted by day 15 after a single dose. Researchers found that mRNA-1273 vaccination-neutralizing antibody titers in eight patients exceeded those seen in convalescent sera. Moreover, the vaccine was generally safe and well-tolerated by participants.

In the phase II study, the company will amend the dose levels, at 50 µg and 100 µg, with the goal of selecting a pivotal dose. The NIAID-led phase I study is also amending doses to include a 50 µg dose level cohort across three age groups.

Phase II and III studies of mRNA-1273 are supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). They are also supporting the scale-up of mRNA-1273 manufacturing at two Moderna facilities as well as at Lonza facilities, a strategic partner of the company.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?